XML 152 R95.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details) € in Millions, $ in Millions |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Sep. 30, 2021 USD ($) | Jul. 01, 2015 agreement | Nov. 30, 2022 EUR (€) | Nov. 30, 2022 USD ($) | Jul. 31, 2022 EUR (€) | Jul. 31, 2022 USD ($) | Dec. 31, 2024 EUR (€) | Dec. 31, 2023 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2015 USD ($)
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |
Other operating income/(expenses), net related to Regeneron |  |  |  |  |  |  | € (3,789) | € (2,979) | € (1,231) |
Non-current assets or disposal groups classified as held for sale |  |  |  |  |  |  | 13,489 | 15 | 85 |
Regeneron Pharmaceuticals, INC |  |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |
Non-current assets or disposal groups classified as held for sale |  |  |  |  |  |  |  |  | 226 |
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement |  |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |
Number of agreements signed | agreement |  | 2 |  |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) |  |  |  |  |  |  |  |  |  | 10.00%
Percentage of cumulative development costs reimbursed |  |  |  |  |  |  |  |  |  | 50.00%
Regular milestone payments for projects under collaboration agreements |  |  | € 96 | $ 100 |  |  |  |  |  |
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement |  |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payments for projects under collaboration agreements |  |  |  |  | € 856 | $ 900 |  |  |  |
Royalty income percentage (percentage) |  |  |  |  | 11.00% | 11.00% |  |  |  |
Other operating income/(expenses), net related to Regeneron |  |  |  |  |  |  |  | 116 | 111 |
Proceeds from collaboration agreements |  |  |  |  |  |  | € 117 | € 196 | € 952 |
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Development of cemiplimab (REGN2810) |  |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |
Prior development budget in total | $ |  |  |  |  |  |  |  |  |  | $ 1,640
Contractual agreement for anti-programmed cell death protein |  |  |  |  |  |  |  |  |  | 5000.00%
Maximum additional funding for PD1 - part of each company | $ | $ 1,840 |  |  |  |  |  |  |  |  | $ 820
PD1 sales milestone payment from Sanofi | $ |  |  |  |  |  |  |  |  |  | 375
Minimum sales of PD1 in 12-month period to be achieved for milestone payment | $ |  |  |  |  |  |  |  |  |  | $ 2,000

X
- Definition The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2023-01-01 -Paragraph 38 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_38&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of operating income (expense) that the entity does not separately disclose in the same statement or note. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 85 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_OtherOperatingIncomeExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Anti programmed cell death protein 1 sales milestone payment. + References No definition available. + Details
Name: | sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contractual Agreement For Anti-programmed Cell Death Protein1 + References No definition available. + Details
Name: | sny_ContractualAgreementForAntiProgrammedCellDeathProtein1
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Disclosure of Principal Alliances [Line Items] + References No definition available. + Details
Name: | sny_DisclosureOfPrincipalAlliancesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum additional funding for anti programmed cell death protein 1 part of each company. + References No definition available. + Details
Name: | sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum sales of anti programmed cell death protein 1 in twelve month period to be achieved for milestone payment. + References No definition available. + Details
Name: | sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number Of Agreements Signed + References No definition available. + Details
Name: | sny_NumberOfAgreementsSigned
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of cumulative development costs reimbursed. + References No definition available. + Details
Name: | sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of profit share on counter parties profit. + References No definition available. + Details
Name: | sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Prior development budget. + References No definition available. + Details
Name: | sny_PriorDevelopmentBudget
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Proceeds From Collaboration Agreements + References No definition available. + Details
Name: | sny_ProceedsFromCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regular Milestone Payments For Projects Under Collaboration Agreements + References No definition available. + Details
Name: | sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Income, Percentage + References No definition available. + Details
Name: | sny_RoyaltyIncomePercentage
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront Payments For Projects Under Collaboration Agreements + References No definition available. + Details
Name: | sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sny_MajorCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_DevelopmentOfCemiplimabREGN2810Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |